| Product Code: ETC13236491 | Publication Date: Apr 2025 | Product Type: Market Research Report | |
| Publisher: 6Wresearch | No. of Pages: 150 | No. of Figures: 55 | No. of Tables: 32 |
North America Antimicrobial Resistance Market |
1 Executive Summary |
2 Introduction |
2.1 Key Highlights of the Report |
2.2 Report Description |
2.3 Market Scope & Segmentation |
2.4 Research Methodology |
2.5 Assumptions |
3 North America Antimicrobial Resistance Market Overview |
3.1 North America Regional Macro Economic Indicators |
3.2 North America Antimicrobial Resistance Market Revenues & Volume, 2021 & 2031F |
3.3 North America Antimicrobial Resistance Market - Industry Life Cycle |
3.4 North America Antimicrobial Resistance Market - Porter's Five Forces |
3.5 North America Antimicrobial Resistance Market Revenues & Volume Share, By Countries, 2021 & 2031F |
3.6 North America Antimicrobial Resistance Market Revenues & Volume Share, By Indication, 2021 & 2031F |
3.7 North America Antimicrobial Resistance Market Revenues & Volume Share, By Drug Class, 2021 & 2031F |
3.8 North America Antimicrobial Resistance Market Revenues & Volume Share, By Mechanism of Action, 2021 & 2031F |
3.9 North America Antimicrobial Resistance Market Revenues & Volume Share, By Pathogen, 2021 & 2031F |
4 North America Antimicrobial Resistance Market Dynamics |
4.1 Impact Analysis |
4.2 Market Drivers |
4.3 Market Restraints |
5 North America Antimicrobial Resistance Market Trends |
6 North America Antimicrobial Resistance Market, 2021 - 2031 |
6.1 North America Antimicrobial Resistance Market, Revenues & Volume, By Indication, 2021 - 2031 |
6.1.1 Overview & Analysis |
6.1.2 North America Antimicrobial Resistance Market, Revenues & Volume, By Complicated Urinary Tract Infections (cUTI), 2021 - 2031 |
6.1.3 North America Antimicrobial Resistance Market, Revenues & Volume, By Blood stream infections, 2021 - 2031 |
6.1.4 North America Antimicrobial Resistance Market, Revenues & Volume, By Acute bacterial skin and skin structure infections (ABSSSI), 2021 - 2031 |
6.1.5 North America Antimicrobial Resistance Market, Revenues & Volume, By Hospital acquired bacterial pneumonia and ventilator acquired bacterial pneumonia (HABP and VABP), 2021 - 2031 |
6.1.6 North America Antimicrobial Resistance Market, Revenues & Volume, By Community acquired pneumonia (CAP), 2021 - 2031 |
6.1.7 North America Antimicrobial Resistance Market, Revenues & Volume, By Others, 2021 - 2031 |
6.2 North America Antimicrobial Resistance Market, Revenues & Volume, By Drug Class, 2021 - 2031 |
6.2.1 Overview & Analysis |
6.2.2 North America Antimicrobial Resistance Market, Revenues & Volume, By Combination therapies, 2021 - 2031 |
6.2.3 North America Antimicrobial Resistance Market, Revenues & Volume, By Tetracyclines, 2021 - 2031 |
6.2.4 North America Antimicrobial Resistance Market, Revenues & Volume, By Cephalosporins, 2021 - 2031 |
6.2.5 North America Antimicrobial Resistance Market, Revenues & Volume, By Glycopeptides and Lipoglycopeptides, 2021 - 2031 |
6.2.6 North America Antimicrobial Resistance Market, Revenues & Volume, By Oxazolidinones, 2021 - 2031 |
6.2.7 North America Antimicrobial Resistance Market, Revenues & Volume, By Others, 2021 - 2031 |
6.3 North America Antimicrobial Resistance Market, Revenues & Volume, By Mechanism of Action, 2021 - 2031 |
6.3.1 Overview & Analysis |
6.3.2 North America Antimicrobial Resistance Market, Revenues & Volume, By Protein Synthesis Inhibitors, 2021 - 2031 |
6.3.3 North America Antimicrobial Resistance Market, Revenues & Volume, By Cell Wall Synthesis Inhibitors, 2021 - 2031 |
6.3.4 North America Antimicrobial Resistance Market, Revenues & Volume, By Others, 2021 - 2031 |
6.4 North America Antimicrobial Resistance Market, Revenues & Volume, By Pathogen, 2021 - 2031 |
6.4.2 North America Antimicrobial Resistance Market, Revenues & Volume, By Klebsiella pneumoniae, 2021 - 2031 |
6.4.3 North America Antimicrobial Resistance Market, Revenues & Volume, By Pseudomonas aeruginosa, 2021 - 2031 |
6.4.4 North America Antimicrobial Resistance Market, Revenues & Volume, By Staphylococcus aureus, 2021 - 2031 |
6.4.5 North America Antimicrobial Resistance Market, Revenues & Volume, By Enterococcus Spp, 2021 - 2031 |
6.4.6 North America Antimicrobial Resistance Market, Revenues & Volume, By Escherichia coli, 2021 - 2031 |
6.4.7 North America Antimicrobial Resistance Market, Revenues & Volume, By Others, 2021 - 2031 |
7 North America Antimicrobial Resistance Market, By Countries, 2021 - 2031 |
7.1 Overview & Analysis |
7.2 North America Antimicrobial Resistance Market, Revenues & Volume, By Indication, 2021 - 2031 |
7.2.1 United States (US) Antimicrobial Resistance Market, Revenues & Volume, By Indication, 2021 - 2031 |
7.2.2 Canada Antimicrobial Resistance Market, Revenues & Volume, By Indication, 2021 - 2031 |
7.2.3 Rest of North America Antimicrobial Resistance Market, Revenues & Volume, By Indication, 2021 - 2031 |
7.3 North America Antimicrobial Resistance Market Revenues & Volume Share, By Drug Class, 2021 & 2031F |
7.3.1 United States (US) Antimicrobial Resistance Market, Revenues & Volume, By Drug Class, 2021 - 2031 |
7.3.2 Canada Antimicrobial Resistance Market, Revenues & Volume, By Drug Class, 2021 - 2031 |
7.3.3 Rest of North America Antimicrobial Resistance Market, Revenues & Volume, By Drug Class, 2021 - 2031 |
7.4 North America Antimicrobial Resistance Market, Revenues & Volume, By Mechanism of Action, 2021 - 2031 |
7.4.1 United States (US) Antimicrobial Resistance Market, Revenues & Volume, By Mechanism of Action, 2021 - 2031 |
7.4.2 Canada Antimicrobial Resistance Market, Revenues & Volume, By Mechanism of Action, 2021 - 2031 |
7.4.3 Rest of North America Antimicrobial Resistance Market, Revenues & Volume, By Mechanism of Action, 2021 - 2031 |
7.5 North America Antimicrobial Resistance Market, Revenues & Volume, By Pathogen, 2021 - 2031 |
7.5.1 United States (US) Antimicrobial Resistance Market, Revenues & Volume, By Pathogen, 2021 - 2031 |
7.5.2 Canada Antimicrobial Resistance Market, Revenues & Volume, By Pathogen, 2021 - 2031 |
7.5.3 Rest of North America Antimicrobial Resistance Market, Revenues & Volume, By Pathogen, 2021 - 2031 |
8 North America Antimicrobial Resistance Market Key Performance Indicators |
9 North America Antimicrobial Resistance Market - Export/Import By Countries Assessment |
10 North America Antimicrobial Resistance Market - Opportunity Assessment |
10.1 North America Antimicrobial Resistance Market Opportunity Assessment, By Countries, 2021 & 2031F |
10.2 North America Antimicrobial Resistance Market Opportunity Assessment, By Indication, 2021 & 2031F |
10.3 North America Antimicrobial Resistance Market Opportunity Assessment, By Drug Class, 2021 & 2031F |
10.4 North America Antimicrobial Resistance Market Opportunity Assessment, By Mechanism of Action, 2021 & 2031F |
10.5 North America Antimicrobial Resistance Market Opportunity Assessment, By Pathogen, 2021 & 2031F |
11 North America Antimicrobial Resistance Market - Competitive Landscape |
11.1 North America Antimicrobial Resistance Market Revenue Share, By Companies, 2022 |
11.2 North America Antimicrobial Resistance Market Competitive Benchmarking, By Operating and Technical Parameters |
12 Top 10 Company Profiles |
13 Recommendations |
14 Disclaimer |
Export potential enables firms to identify high-growth global markets with greater confidence by combining advanced trade intelligence with a structured quantitative methodology. The framework analyzes emerging demand trends and country-level import patterns while integrating macroeconomic and trade datasets such as GDP and population forecasts, bilateral import–export flows, tariff structures, elasticity differentials between developed and developing economies, geographic distance, and import demand projections. Using weighted trade values from 2020–2024 as the base period to project country-to-country export potential for 2030, these inputs are operationalized through calculated drivers such as gravity model parameters, tariff impact factors, and projected GDP per-capita growth. Through an analysis of hidden potentials, demand hotspots, and market conditions that are most favorable to success, this method enables firms to focus on target countries, maximize returns, and global expansion with data, backed by accuracy.
By factoring in the projected importer demand gap that is currently unmet and could be potential opportunity, it identifies the potential for the Exporter (Country) among 190 countries, against the general trade analysis, which identifies the biggest importer or exporter.
To discover high-growth global markets and optimize your business strategy:
Click Here